At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...